₹ 546.45 -2.40 (-0.44%)
- NSE
- BSE
Overview
- BSE Code 544172
- NSE Symbol INDGN
- ISIN Demat INE065X01017
- Book Value (₹) 78.62
- Face Value (₹) 2.00
- Market Cap (₹ Cr.) 13,784.80
- P/E (TTM) 77.18
- EPS (TTM) 7.44
- Div Yield (%) 0.35
Performance
Corporate Actions
Indegene Limited - Dividend
Apr 28, 2025Indegene Limited has informed the Exchange that Board of Directors at its meeting held on April 28, 2025, recommended Final Dividend of 2 per equity share.
Indegene Limited - Dividend
Apr 28, 2025Indegene Limited has informed the Exchange that Board of Directors at its meeting held on April 28, 2025, recommended Final Dividend of Rs. 2 per equity share.
Indegene Limited - Outcome of Board Meeting
Apr 28, 2025Indegene Limited has informed the Exchange regarding Outcome of Board Meeting held on April 28, 2025.
Indegene Limited - Outcome of Board Meeting-XBRL
Apr 28, 2025INDEGENE LIMITED has informed the Exchange regarding Outcome of Board Meeting held on 28-Apr-2025 for Dividend
Indegene Limited - Press Release
Apr 28, 2025Indegene Limited has informed the Exchange regarding a press release dated April 28, 2025, titled "Press Release - Financial results for the quarter and financial year ended March 31, 2025".
Indegene Limited - Investor Presentation
Apr 28, 2025Indegene Limited has informed the Exchange about Investor Presentation
Indegene Limited - Alteration Of Capital and Fund Raising-XBRL
Apr 28, 2025INDEGENE LIMITED has informed the Exchange regarding Allotment of Securities
Indegene Limited - Monitoring Agency Report
Apr 28, 2025Monitoring Agency Report for the quarter ended March 31, 2025
About Indegene Ltd
Indegene Limited was established as Indegene Lifesystems Private Limited' at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to Indegene Private Limited' and a fresh Certificate of Incorporation was as registered with the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to Indegene Limited' on November 17, 2022.
the Company is a global provider of solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and healthcare organizations. It provide digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech and medical devices companies, that assist them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products.
Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a 'digital first' approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients.
Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analytics
in helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals.
In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies.
In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited.
On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021.
the Company acquired Cult Health, a full-service healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022.
the Company launched Invisage, an AI-enabled hybrid omnichannel sales and marketing platform in 2023.
the Company made a public issue of 40,766,550 Equity Shares of face value of Rs 2 each by raising funds aggregating to Rs. 1842 Crore comprising a fresh issue of 16,833,818 Equity Shares aggregating to Rs. 760 Crore and 23,932,732 Equity Shares aggregating to Rs 1082 Crore through Offer for Sale in May, 2024.
In 2024, the Company acquired a controlling stake in Trilogy Writing & Consulting GmbH.
Founded | : 1998 |
Chairman | : Manish Gupta |
Address | : Aspen Block G4 3rd Flr Manyata, Embassy Busi. Park Nagawara, Bengaluru, Karnataka, 560045, |
- PAN Card
- Cancelled Cheque
- Latest 6 month Bank Statement (Only for Derivatives Trading)